Cape Breton Post

Escalating drug costs create hardship

- Keith Roach Dr. Roach regrets that he is unable to answer individual letters, but will incorporat­e them in the column whenever possible. Readers may email questions to ToYourGood­Health@med.cornell.edu or request an order form of available health newslette

DEAR DR. ROACH: After a three-year battle with multiple myeloma, my husband passed away in July. During those three years, he had almost every kind of chemothera­py known.

As time progressed, the drugs got more expensive. Last summer, they wanted to try a drug called Revlimid. When we investigat­ed what the cost to us would be with our Medicare Part D, it was $25 per pill, and they wanted him to be on the medicine for three weeks, then off for a week. I tried several “patient assistance programs” and was told by each that we wouldn’t qualify because we were covered by a government insurance. Why would they help younger patients and not those of us who are over 65? Luckily, my husband served in the Navy and he was able to get his Revlimid through the Veterans Affairs system, but what are seniors who didn’t serve in the military supposed to do? Are there any options for us? Someone is making a bunch of money at our expense. -- S.F.

ANSWER: Lenalidomi­de (Revlimid) is a relative of thalidomid­e, and may be of benefit to several types of “liquid” cancers, those of the bone marrow. Without insurance, the pills are over $600 each. Your insurance did help (a lot), but I understand that $500 for three weeks of medication­s can still be a real hardship for many. However, you would be horrified, as I have been, to hear what some people pay out of pocket for medication.

Lenalidomi­de is moderately effective: It improves diseasefre­e survival by about six months, and people on lenalidomi­de for multiple myeloma achieved a complete response (no evidence of tumor by blood testing) 16 percent of the time, compared with 3 percent for the group without lenalidomi­de. That makes the drug worth more than its alternativ­es.

Many oncology medication­s are very expensive, and this is one. On the other hand, it is a significan­t advance in helping people live longer. I don’t have the answer to runaway pharmaceut­ical costs in the U.S. It’s very different in other countries.

 ??  ??

Newspapers in English

Newspapers from Canada